Navigation Links
IDM Pharma Reports Third Quarter 2007 Financial Results
Date:11/8/2007

low a more robust analysis of L-MTP- PE, will not continue to support its overall survival benefit in osteosarcoma, and may not provide substantial evidence for the potential regulatory approval of L-MTP-PE, the timing of the FDA's and EMEA's review of the submissions for marketing approval of L-MTP-PE, the ability of the Company to respond to questions raised by the FDA and EMEA in a satisfactory manner, the time needed to respond to any issues raised by the FDA and EMEA with regard to regulatory submissions for L-MTP-PE, the possibility that regulatory authorities may not consider preclinical and early clinical development work conducted by Ciba-Geigy and efficacy data from the Phase 3 trial conducted by Children's Oncology Group as adequate for their assessment of L-MTP-PE, which may cause delays in review, may result in the regulatory authorities requiring the Company to conduct additional clinical trials, or may result in a determination by the regulatory authorities that the data does not support marketing approval, whether regulatory authorities will approve L-MTP-PE within the time frame expected by the Company or at all, and whether the Company will be able to manufacture and commercialize L-MTP-PE even if it is approved by regulatory authorities. Other risks affecting the Company and its drug development programs include whether the Company or any of its collaborators will be able to develop pharmaceutical products using the technologies of the Company, whether clinical trial results to date are predictive of results of any future clinical trials, risks associated with completing clinical trials of product candidates, risks involved in the regulatory approval process for the Company's product candidates, the possibility that clinical testing may reveal undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products; whether the cash resources of the Company will be sufficient to fund operat
'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Between 23 million and 50 million people suffer ... from the National Institutes of Health (NIH) and the ... them have something else in common: They have a ... Gluten Free Therapeutics, makers of CeliVites nutritional supplements, ... publishing a series of blog posts aimed at educating ...
(Date:10/1/2014)... 2014 NoteSwift Inc., announced today their ... 12.1 and 13.0. NoteSwift is the bridge between the ... navigate and document clinical information at the point of ... a patient note by more than half – and ... pain points providers state impedes EHR use according to ...
(Date:10/1/2014)... 2014 On Sept. 9, Chapín Coffee ... the Martha Stewart American Made Awards (MSAMAs), an annual ... country in the fields of crafts, design, food and ... a finalist in the MSAMAs, which celebrates entrepreneurs and ... improving local communities and changing the way we shop, ...
(Date:10/1/2014)... October is national Breast Cancer Awareness Month—an ... while raising money for breast cancer research. Pelican Water ... in the effort to find a cure. ... of having access to clean, healthy water. Research has ... certain forms of cancer. , The Problem of ...
(Date:10/1/2014)... OXNARD, CA (PRWEB) October 01, 2014 ... of the Anacapa Dental Art Institute in Oxnard and ... of Bangalore providing full mouth rehabilitation training. , “Speaking ... need of these transformative procedures to get the help ... mouth rehabilitation may involve repairing previous dental work, providing ...
Breaking Medicine News(10 mins):Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 2Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 3Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 4Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 5
... syndrome) has been a major killer in the last two ... worldwide and infected a further 8,000. A collaborative group of ... past year screening more than 8,000 existing drugs to find ... 15 existing drugs that have the potential to kill the ...
... the womb of the mother, may have asthma at a ... an 11-year observation of incidence of asthma and other respiratory ... to incidence of asthma in childhood. Passive smoking by the ... of asthma in children. ,Researchers are of the opinion ...
... Parkinson's disease is a neurodegenerative disease of the substantia nigra ... first discovered and its symptoms documented in 1817 by the ... in the brain of patients were identified in the 1960s. ... a mystery. , ,In a study done recently it ...
... have found sections of the // chromosomes of lung ... ,In a study in the July 1 issue ... nucleotide polymorphism (SNP) array technology, which focuses on the ... chromosomes where genes were either left out or multiplied ...
... autistic children have led to a fear in the world ... epidemic. However a recent report, which was published in the ... is not true. The report points out to certain facts ... ,The study had pointed out that recent changes in the ...
... that walking on a cobblestone mat surface resulted in ... physical performance among the age groups of 60 and ... said that Compared to conventional walking, the experience ... manufactured cobblestone mats improved participants' balance, measures of mobility, ...
Cached Medicine News:Health News:Re –growing Brain cells destroyed by Parkinson’s disease 2Health News:Possible location of lung cancer genes found 2Health News:Cobblestone Walking May Be The Key For Healthy Living. 2
(Date:9/30/2014)... Mass. , Sept. 30, 2014  Hologic, Inc. ... Stephen MacMillan , Hologic,s President and Chief Executive Officer, ... Ceremony on October 1, the first day of Breast ... discuss the Company,s campaign focused on the important benefits ... approved by the FDA as clinically superior to traditional ...
(Date:9/30/2014)... , Sept. 30, 2014 This ... for molecular imaging informatics solutions including nuclear imaging ... and comparison. The study assesses the size of ... 2010 and 2013, and projects future growth based ... as the dynamics taking place in the broader ...
(Date:9/30/2014)... , Sept. 30, 2014 Aileron Therapeutics, ... Summary Global Markets Direct,s, ,Aileron Therapeutics, Inc. ... overview of the Aileron Therapeutics, Inc.,s pharmaceutical research ... information on the current therapeutic developmental pipeline of ... various stages, therapeutics assessment by drug target, mechanism ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3
... nationally recognized, certified practice management and electronic ... its annual Customer Conference at the Magic City,s renowned ... A record 361 attendees registered for this ... last year,s figures. "Spotlight on Success" was chosen as ...
... RIDGEFIELD, Conn., May 19, 2011 Boehringer Ingelheim ... (dabigatran etexilate mesylate) capsules has received preferred ... Part D plans through its pharmacy benefits manager, ... include AARP Medicare Rx and AARP MedicareComplete from ...
Cached Medicine Technology:SuccessEHS "Spotlight on Success" Customer Conference Begins 2Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 2Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 3Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 4Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 5Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 6